{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T14:19:13Z","timestamp":1782569953363,"version":"3.54.5"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nuclear Medicine and Biology"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.nucmedbio.2022.06.005","type":"journal-article","created":{"date-parts":[[2022,6,30]],"date-time":"2022-06-30T02:11:09Z","timestamp":1656555069000},"page":"44-51","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Organic cation transporter 3 mediates the non-norepinephrine transporter driven uptake of meta-[211At]astato-benzylguanidine"],"prefix":"10.1016","volume":"112-113","author":[{"given":"Yasuhiro","family":"Ohshima","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ichiro","family":"Sasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeki","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuya","family":"Sakashita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuya","family":"Higashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriko S.","family":"Ishioka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nucmedbio.2022.06.005_bb0005","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.critrevonc.2018.01.001","article-title":"Global comparison of targeted alpha vs targeted beta therapy for cancer: in vitro, in vivo and clinical trials","volume":"123","author":"Marcu","year":"2018","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.nucmedbio.2022.06.005_bb0010","doi-asserted-by":"crossref","first-page":"30","DOI":"10.2967\/jnumed.107.046938","article-title":"Clinical experience with alpha-particle emitting 211At: treatment of recurrent brain tumor patients with 211At-labeled chimeric antitenascin monoclonal antibody 81C6","volume":"49","author":"Zalutsky","year":"2008","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2022.06.005_bb0015","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1007\/s00259-014-2857-9","article-title":"213Bi-DOTATOC receptor-targeted alpha-radionuclide therapy induces remission in neuroendocrine tumours refractory to beta radiation: a first-in-human experience","volume":"41","author":"Kratochwil","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.nucmedbio.2022.06.005_bb0020","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1097\/COC.0000000000000353","article-title":"Safety and outcome measures of first-in-human intraperitoneal \u03b1 radioimmunotherapy with 212Pb-TCMC-trastuzumab","volume":"41","author":"Meredith","year":"2018","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.nucmedbio.2022.06.005_bb0025","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.2967\/jnumed.116.178673","article-title":"225Ac-PSMA-617 for PSMA-targeted \u03b1-radiation therapy of metastatic castration-resistant prostate cancer","volume":"57","author":"Kratochwil","year":"2016","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2022.06.005_bb0030","doi-asserted-by":"crossref","first-page":"669","DOI":"10.2967\/jnumed.120.251017","article-title":"First clinical results for PSMA-targeted \u03b1-therapy using 225Ac-PSMA-I&T in advanced-mCRPC patients","volume":"62","author":"Zacherl","year":"2021","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2022.06.005_bb0035","article-title":"Effects of 225Ac-labeled prostate-specific membrane antigen radioligand therapy in metastatic castration-resistant prostate cancer: a meta-analysis","author":"Lee","year":"2021","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2022.06.005_bb0040","doi-asserted-by":"crossref","first-page":"8941","DOI":"10.1158\/0008-5472.CAN-09-1828","article-title":"Radioimmunotherapy of breast cancer metastases with alpha-particle emitter 225Ac: comparing efficacy with 213Bi and 90Y","volume":"69","author":"Song","year":"2009","journal-title":"Cancer Res"},{"key":"10.1016\/j.nucmedbio.2022.06.005_bb0045","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1007\/s00259-017-3919-6","article-title":"Antitumor effects of radionuclide treatment using \u03b1-emitting meta-211At-astato-benzylguanidine in a PC12 pheochromocytoma model","volume":"45","author":"Ohshima","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.nucmedbio.2022.06.005_bb0050","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.7150\/thno.30353","article-title":"Anti-tumor effects and potential therapeutic response biomarkers in \u03b1-emitting meta-211At-astato-benzylguanidine therapy for malignant pheochromocytoma explored by RNA-sequencing","volume":"9","author":"Ohshima","year":"2019","journal-title":"Theranostics"},{"key":"10.1016\/j.nucmedbio.2022.06.005_bb0055","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.tranon.2019.04.008","article-title":"Preclinical evaluation of the acute radiotoxicity of the \u03b1-emitting molecular-targeted therapeutic agent [211At]MABG for the treatment of malignant pheochromocytoma in normal mice","volume":"12","author":"Sudo","year":"2019","journal-title":"Transl Oncol."},{"key":"10.1016\/j.nucmedbio.2022.06.005_bb0060","first-page":"897","article-title":"Effect of uptake-one inhibitors on the uptake of norepinephrine and metaiodobenzylguanidine","volume":"26","author":"Tobes","year":"1985","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2022.06.005_bb0065","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.nucmedbio.2008.12.010","article-title":"Uptake of mIBG and catecholamines in noradrenaline- and organic cation transporter-expressing cells: potential use of corticosterone for a preferred uptake in neuroblastoma- and pheochromocytoma cells","volume":"36","author":"Bayer","year":"2009","journal-title":"Nucl Med Biol"},{"key":"10.1016\/j.nucmedbio.2022.06.005_bb0070","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1124\/mol.120.119495","article-title":"Characterization of meta-iodobenzylguanidine (mIBG) transport by polyspecific organic cation transporters: implication for mIBG therapy","volume":"98","author":"Quinones","year":"2020","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.nucmedbio.2022.06.005_bb0075","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1124\/jpet.103.053298","article-title":"Pharmacological and physiological functions of the polyspecific organic cation transporters: OCT1, 2, and 3 (SLC22A1-3)","volume":"308","author":"Jonker","year":"2004","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.nucmedbio.2022.06.005_bb0080","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1124\/mol.51.6.913","article-title":"Cloning and functional expression of a human liver organic cation transporter","volume":"51","author":"Zhang","year":"1997","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.nucmedbio.2022.06.005_bb0085","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1089\/dna.1997.16.871","article-title":"Cloning and characterization of two human polyspecific organic cation transporters","volume":"16","author":"Gorboulev","year":"1997","journal-title":"DNA Cell Biol"},{"key":"10.1016\/j.nucmedbio.2022.06.005_bb0090","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1006\/geno.1998.5639","article-title":"Cloning of the mouse and human solute carrier 22a3 (Slc22a3\/SLC22A3) identifies a conserved cluster of three organic cation transporters on mouse chromosome 17 and human 6q26-q27","volume":"55","author":"Verhaagh","year":"1999","journal-title":"Genomics"},{"key":"10.1016\/j.nucmedbio.2022.06.005_bb0095","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.ijrobp.2015.11.046","article-title":"Radiation-related new primary solid cancers in the childhood cancer survivor study: comparative radiation dose response and modification of treatment effects","volume":"94","author":"Inskip","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.nucmedbio.2022.06.005_bb0100","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1038\/nrc3069","article-title":"Assessing the risk of second malignancies after modern radiotherapy","volume":"11","author":"Newhauser","year":"2011","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.nucmedbio.2022.06.005_bb0105","first-page":"5414","article-title":"Cytotoxicity of alpha-particle-emitting m-[211At]astatobenzylguanidine on human neuroblastoma cells","volume":"54","author":"Strickland","year":"1994","journal-title":"Cancer Res"},{"key":"10.1016\/j.nucmedbio.2022.06.005_bb0110","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/0969-8051(96)00115-1","article-title":"Evaluation of meta-[211At]astatobenzylguanidine in an athymic mouse human neuroblastoma xenograft model","volume":"23","author":"Vaidyanathan","year":"1996","journal-title":"Nucl Med Biol"},{"key":"10.1016\/j.nucmedbio.2022.06.005_bb0115","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1007\/s11095-007-9254-z","article-title":"Polyspecific organic cation transporters: structure, function, physiological roles, and biopharmaceutical implications","volume":"24","author":"Koepsell","year":"2007","journal-title":"Pharm Res"},{"key":"10.1016\/j.nucmedbio.2022.06.005_bb0120","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1007\/s12098-008-0208-1","article-title":"Corticosteroid physiology and principles of therapy","volume":"75","author":"Gupta","year":"2008","journal-title":"Indian J Pediatr"},{"key":"10.1016\/j.nucmedbio.2022.06.005_bb0125","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0969-8051(94)00084-W","article-title":"Uptake mechanisms of meta-[123I]iodobenzylguanidine in isolated rat heart","volume":"22","author":"Degrado","year":"1995","journal-title":"Nucl Med Biol"},{"key":"10.1016\/j.nucmedbio.2022.06.005_bb0130","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.yhbeh.2018.05.003","article-title":"Organic cation transporter 3: a cellular mechanism underlying rapid, non-genomic glucocorticoid regulation of monoaminergic neurotransmission, physiology, and behavior","volume":"104","author":"Gasser","year":"2018","journal-title":"Horm Behav"},{"issue":"Suppl 6","key":"10.1016\/j.nucmedbio.2022.06.005_bb0135","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1093\/ndt\/15.suppl_6.3","article-title":"Polyspecific cation transporters in the proximal tubule","volume":"15","author":"Koepsell","year":"2000","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nucmedbio.2022.06.005_bb0140","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/1557","article-title":"Molecular identification of the corticosterone-sensitive extraneuronal catecholamine transporter","volume":"1","author":"Gr\u00fcndemann","year":"1998","journal-title":"Nat Neurosci"},{"key":"10.1016\/j.nucmedbio.2022.06.005_bb0145","doi-asserted-by":"crossref","first-page":"32776","DOI":"10.1074\/jbc.273.49.32776","article-title":"Identity of the organic cation transporter OCT3 as the extraneuronal monoamine transporter (uptake2) and evidence for the expression of the transporter in the brain","volume":"273","author":"Wu","year":"1998","journal-title":"J Biol Chem"},{"key":"10.1016\/j.nucmedbio.2022.06.005_bb0150","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1210\/endo.139.2.5724","article-title":"KAT45, a noradrenergic human pheochromocytoma cell line producing corticotropin-releasing hormone","volume":"139","author":"Venihaki","year":"1998","journal-title":"Endocrinology"},{"key":"10.1016\/j.nucmedbio.2022.06.005_bb0155","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.nucmedbio.2016.05.013","article-title":"Improved selectivity of mIBG uptake into neuroblastoma cells in vitro and in vivo by inhibition of organic cation transporter 3 uptake using clinically approved corticosteroids","volume":"43","author":"Bayer","year":"2016","journal-title":"Nucl Med Biol"},{"key":"10.1016\/j.nucmedbio.2022.06.005_bb0160","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/BF01062332","article-title":"Effect of dose size on the pharmacokinetics of intravenous hydrocortisone during endogenous hydrocortisone suppression","volume":"10","author":"Toothaker","year":"1982","journal-title":"J Pharmacokinet Biopharm"},{"key":"10.1016\/j.nucmedbio.2022.06.005_bb0165","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1161\/01.CIR.31.4.523","article-title":"Acute pharmacodynamic effects of glucocorticoids; cardiac output and related hemodynamic changes in normal subjects and patients in shock","volume":"31","author":"Sambhi","year":"1965","journal-title":"Circulation"},{"key":"10.1016\/j.nucmedbio.2022.06.005_bb0170","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1080\/20009666.2021.1964164","article-title":"Role of steroids in critically-ill sepsis patients: a review article and literature to review","volume":"11","author":"Mirza","year":"2021","journal-title":"J Community Hosp Intern Med Perspect"},{"key":"10.1016\/j.nucmedbio.2022.06.005_bb0175","doi-asserted-by":"crossref","first-page":"433","DOI":"10.2165\/00003088-200645050-00001","article-title":"The influence of cardiovascular physiology on dose\/pharmacokinetic and pharmacokinetic\/pharmacodynamic relationships","volume":"45","author":"Fagiolino","year":"2006","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.nucmedbio.2022.06.005_bb0180","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1053\/j.semnuclmed.2011.05.003","article-title":"Radioiodinated metaiodobenzylguanidine (MIBG): radiochemistry, biology, and pharmacology","volume":"41","author":"Vallabhajosula","year":"2011","journal-title":"Semin Nucl Med"}],"container-title":["Nuclear Medicine and Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969805122020649?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969805122020649?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T04:30:43Z","timestamp":1760848243000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0969805122020649"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":36,"alternative-id":["S0969805122020649"],"URL":"https:\/\/doi.org\/10.1016\/j.nucmedbio.2022.06.005","relation":{},"ISSN":["0969-8051"],"issn-type":[{"value":"0969-8051","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Organic cation transporter 3 mediates the non-norepinephrine transporter driven uptake of meta-[211At]astato-benzylguanidine","name":"articletitle","label":"Article Title"},{"value":"Nuclear Medicine and Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nucmedbio.2022.06.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}